Health Organizations

here are the key takeaways from the text, focusing on the sisters’ story and the research‌ developments:

Silvia and Elena’s Story:

* ​ ⁣ Silvia ⁤needed a kidney transplant and began dialysis.
* Elena, ‌Silvia’s ‍sister, volunteered to donate⁣ a kidney. Initially⁣ hesitant due to her children, she was inspired ‍by their mother’s experience with a kidney removal and long life afterward.
* ‌ The donation process was rigorous, involving ⁢extensive medical ​and ⁢psychological evaluations⁤ to ensure it was a genuine and informed decision.
* Both sisters feel positively⁣ impacted by ⁤the transplant. Elena describes it as “giving birth to another⁣ child,” and ‌Silvia acknowledges the immense ⁢strength‌ of ‌the gesture.
* ⁣ Both sisters ⁤are‌ now living normal lives and actively involved in volunteer work.

Research Developments (Mario Negri Institute):

* ​ Silvia participated in ‌a Mario Negri trial aimed at eliminating the need ⁢for anti-rejection therapy. She received mesenchymal cells before the ‌transplant and has as⁣ been able to completely eliminate ‍immunosuppressants as of⁢ January ⁤of the current year.
* ‍ The ⁣initial results of ‌the​ trial were promising.

* ​ Ongoing and future research:

* A new study called “Phoenix” ⁢is ⁣underway ‌with ⁢international collaboration ⁢(Canada, Spain, France).
* ‍ A potential “cell farm” for transplants is being considered at⁢ Kilometro Rosso in Bergamo.
⁢ * ‍ An Irish organization is seeking EU funding for related research.
* A​ new transplant Immunology Laboratory ​will​ open at Kilometro Rosso in​ 2026, building on 15 years of experience.
* Strong collaboration between Mario Negri and Pope John XXIII Hospital on transplant research, ⁤kidney diseases, diabetes, ⁤rare and neurological diseases.
* The institute receives many requests for treatment highlighting the need⁣ for continued investment ⁣in research.

The text emphasizes the power of organ donation, the importance of ‍research in improving ⁣transplant outcomes (specifically reducing ⁢or eliminating the need ⁢for ⁢immunosuppressants), and⁤ the collaborative spirit driving advancements in the field.